Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $147,533.25 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $6.94 on Friday. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -5.26 and a beta of 1.22. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $7.95 and a two-hundred day moving average of $8.92. Ocular Therapeutix, Inc. has a twelve month low of $4.06 and a twelve month high of $11.77.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds have recently modified their holdings of OCUL. GF Fund Management CO. LTD. acquired a new position in Ocular Therapeutix in the 4th quarter valued at $28,000. Atlas Capital Advisors Inc. acquired a new position in shares of Ocular Therapeutix during the fourth quarter worth about $43,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 1,015 shares during the period. AlphaQuest LLC purchased a new position in Ocular Therapeutix during the fourth quarter worth about $53,000. Finally, Capital Performance Advisors LLP acquired a new stake in Ocular Therapeutix in the third quarter valued at about $70,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.